MedTrace Logo

Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6-17

NCT00150592 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 182

Last updated 2021-06-10

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the effects of SPD503 compared to placebo on tasks of sustained attention in children and adolescents aged 6-17 diagnosed with ADHD.

Conditions

  • Attention Deficit Disorder With Hyperactivity

Interventions

DRUG

SPD503 (Guanfacine HCl)

DRUG

Placebo

Sponsors & Collaborators

  • Shire

    lead INDUSTRY

Principal Investigators

  • Study Director · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-12
Primary Completion
2005-10-05
Completion
2005-10-05

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00150592 on ClinicalTrials.gov